Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina
Background: Dopamine agonists (DA) effectively reduce tumor size of macroprolactinomas, with the consequent improvement of eventual visual impairment. Aim: To study the visual outcomes in patients with macroprolactinoma treated with DA. Material and Methods: Retrospective cohort study which included...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2013
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013000600001 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:scielo:S0034-98872013000600001 |
|---|---|
| record_format |
dspace |
| spelling |
oai:scielo:S0034-988720130006000012013-10-08Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopaminaCuevas,José LuisFernández,VerónicaRojas,DavidWohllk,NelsonGonzález,ÓscarTorche,Esteban Dopamine agonist Prolactinoma Visual acuity Visual fields Background: Dopamine agonists (DA) effectively reduce tumor size of macroprolactinomas, with the consequent improvement of eventual visual impairment. Aim: To study the visual outcomes in patients with macroprolactinoma treated with DA. Material and Methods: Retrospective cohort study which included patients with macroprolactinoma controlled at a Neuro-endocrinology and Neuro-ophthalmology Department between 1997'and2011, and treated exclusively with DA (bromocriptine or cabergoline). Patients who were operated or had previous radiotherapy and those with an incomplete follow up, were excluded. We analyzed and compared the visual status before and after the beginning of DA treatment. Results: Thirty one patients aged 8 to 59years, were included. Eighteen patients (58%) had visual impairment at the moment of diagnosis (group 1) and 13 had no alterations (group 2). Mean follow up was 36.5 months. Fifteen patients from group 1 (83%) had visual improvement, two remained stable (11 %) and one had a visual deterioration (6%). In group 2, only one non-compliant patient had a visual deterioration. Conclusions: DAs are effective in the management of neuro-ophthalmic complications associated to macroprolactinomas and should be considered asfirst choice therapy in these tumors.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.141 n.6 20132013-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013000600001es10.4067/S0034-98872013000600001 |
| institution |
Scielo Chile |
| collection |
Scielo Chile |
| language |
Spanish / Castilian |
| topic |
Dopamine agonist Prolactinoma Visual acuity Visual fields |
| spellingShingle |
Dopamine agonist Prolactinoma Visual acuity Visual fields Cuevas,José Luis Fernández,Verónica Rojas,David Wohllk,Nelson González,Óscar Torche,Esteban Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina |
| description |
Background: Dopamine agonists (DA) effectively reduce tumor size of macroprolactinomas, with the consequent improvement of eventual visual impairment. Aim: To study the visual outcomes in patients with macroprolactinoma treated with DA. Material and Methods: Retrospective cohort study which included patients with macroprolactinoma controlled at a Neuro-endocrinology and Neuro-ophthalmology Department between 1997'and2011, and treated exclusively with DA (bromocriptine or cabergoline). Patients who were operated or had previous radiotherapy and those with an incomplete follow up, were excluded. We analyzed and compared the visual status before and after the beginning of DA treatment. Results: Thirty one patients aged 8 to 59years, were included. Eighteen patients (58%) had visual impairment at the moment of diagnosis (group 1) and 13 had no alterations (group 2). Mean follow up was 36.5 months. Fifteen patients from group 1 (83%) had visual improvement, two remained stable (11 %) and one had a visual deterioration (6%). In group 2, only one non-compliant patient had a visual deterioration. Conclusions: DAs are effective in the management of neuro-ophthalmic complications associated to macroprolactinomas and should be considered asfirst choice therapy in these tumors. |
| author |
Cuevas,José Luis Fernández,Verónica Rojas,David Wohllk,Nelson González,Óscar Torche,Esteban |
| author_facet |
Cuevas,José Luis Fernández,Verónica Rojas,David Wohllk,Nelson González,Óscar Torche,Esteban |
| author_sort |
Cuevas,José Luis |
| title |
Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina |
| title_short |
Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina |
| title_full |
Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina |
| title_fullStr |
Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina |
| title_full_unstemmed |
Resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina |
| title_sort |
resultados visuales en pacientes con macroprolactinoma tratados con agonistas de dopamina |
| publisher |
Sociedad Médica de Santiago |
| publishDate |
2013 |
| url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013000600001 |
| work_keys_str_mv |
AT cuevasjoseluis resultadosvisualesenpacientesconmacroprolactinomatratadosconagonistasdedopamina AT fernandezveronica resultadosvisualesenpacientesconmacroprolactinomatratadosconagonistasdedopamina AT rojasdavid resultadosvisualesenpacientesconmacroprolactinomatratadosconagonistasdedopamina AT wohllknelson resultadosvisualesenpacientesconmacroprolactinomatratadosconagonistasdedopamina AT gonzalezoscar resultadosvisualesenpacientesconmacroprolactinomatratadosconagonistasdedopamina AT torcheesteban resultadosvisualesenpacientesconmacroprolactinomatratadosconagonistasdedopamina |
| _version_ |
1718436693172813824 |